RXST
$7.30-0.18 (-2.34%)
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that ena...
Recent News
How The RxSight (RXST) Investment Story Is Shifting With New Guidance And CFO Change
RxSight’s blended fair value estimate has edged down to US$10.17 from US$10.39, reflecting a modest recalibration in the latest round of research updates. Analysts are largely sticking with neutral ratings and fine tuning their targets in a tight band, as they weigh softer 2026 revenue guidance against a slightly firmer revenue trajectory for 2025 and a new CFO stepping into the role. Read on to see how you can track these shifting targets and what they might mean for your own view on...
RxSight, Inc. Q4 2025 Earnings Call Summary
Moby summary of RxSight, Inc.'s Q4 2025 earnings call
RxSight Q4 Earnings Call Highlights
RxSight (NASDAQ:RXST) reported fourth-quarter 2025 revenue of $32.6 million, down 19% year-over-year, driven primarily by lower Light Delivery Device (LDD) sales following an unusually strong prior-year comparison. Management said results were consistent with the company’s January pre-announcement a
RxSight Inc (RXST) Q4 2025 Earnings Call Highlights: Navigating Challenges with Strategic ...
Despite a dip in quarterly revenue, RxSight Inc (RXST) focuses on global growth and innovation to drive future success.
RxSight, Inc. (RXST) Reports Q4 Loss, Beats Revenue Estimates
RxSight (RXST) delivered earnings and revenue surprises of +87.14% and +0.02%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?